Pharmacokinetic Modifications and Drug-Drug Interactions in Clinical Monitoring of the Elderly: A Short Review

Luis Eduardo M. Quintas1*, Karla Regina S. Gram2*, Gabriel Parreiras Estolano da Silveira2, Daniele Valentim S. Lopes4 and Elisa Suzana Carneiro Póças1,5

1Laboratory of Biochemical and Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro/RJ, Brazil
2Project Coordinates Services – Latam, Pharmaceuticals Section, Kendle International, Rio de Janeiro/RJ, Brazil
3Pharmacokinetic Service, Institute of Clinical Research Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro/RJ, Brazil
4Grande Rio University, Duque de Caxias/RJ, Brazil
5Federal Institute of Education, Science and Technology of Rio de Janeiro, Rio de Janeiro/RJ, Brazil

Abstract

The combination of drugs may be a result of a necessary therapeutic strategy against a single disease or a fortuitous treatment of two or more health disorders. In either case, a consequence of such approach is the increased risk of drug interactions and subsequent adverse effects. For the elderly, the probability of these events is significantly increased compared to other age groups, not only because of combining medications but also age-related pharmacokinetic (absorption, distribution, biotransformation and excretion processes) alteration. Since the growth rate of the elderly population worldwide is rapidly increasing, clinicians should be extremely cautious of the drugs prescribed to older patients in order to minimize drug interactions and therapeutic failure.

Keywords: Aging; Pharmacology; Polypharmacy; Adverse drug reactions; Geriatrics

Introduction

Combination drug therapy is a common practice in clinical medicine. They are often used as an approach to enhance the desired pharmacological effect (e.g., paracetamol and codeine), prevention of resistance (e.g., β-lactam antibiotics and β-lactamase inhibitors), or yet the prevention of adverse side effects (interactions of physiological or pharmacological antagonism). All of these approaches intend to ensure greater efficacy of and patient adherence to the pharmacological treatment, since they aim to maximize drug effects and reduce the possible undesirable effects generated due to their use.

Despite seemingly adequate, and many times necessary, the employment of more than one drug to treat a given disease should be conducted judiciously and carefully because of the risk of dangerous drug interactions. However, combination chemotherapy, also known as polypharmacy, and particularly the adverse effects caused by them, is a very poorly explored and even neglected factor in clinical practice [1,2]. Epidemiological studies indicate that adverse drug reactions (ADRs) produced by drug interactions affect progressively the probability of potential interactions through combinatorial analysis of monitoring and professional care. Hypothetically, the estimation of probabilities of potential interactions through combinatorial analysis reveals, for example, that co-administration of 3, 5 or 7 drugs provides interaction chances of 15, 50 or 100%, respectively [3]. Furthermore, over 80% of registered ADRs are characterized as type A, i.e., arising from an exaggerated, dose-dependent drug effect and, by definition, are predictable and preventable, in contrast to the low prevalence of type B ADRs, i.e., unexpected reactions and disconnected from the action of the drug (idiopathic) [4]. The major drug classes responsible for type A are antibiotics, anticoagulants, positive inotropic agents, diuretics, antibacterial agents, non-steroidal anti-inflammatory drugs (NSAIDs), opioids and antineoplastics [4].

In the elderly population, the development of ADRs related to drug interactions is even more complicated because the existence of chronic diseases, polypharmacy, inadequate identification by and information to the patient of the effects of the prescribed drugs, noncompliance to the therapeutic regimen, self-medication, nutritional problems, reduction of financial resources and physiological changes related to aging (Table 1) increase the risk of the manifestation of unwanted interactions [5]. In fact, the latter seems to be a major challenge for the rational prescription of drugs in this population group [6,7]. According to the fertility rates and longevity worldwide, the percentage of elderly is increasing faster than the rest of the population. In developing countries like Brazil, for instance, the estimate for 2020 is 30 million people above 60 years of age (about 13% of the population), while in European countries and in the United States the current fraction of this group is over 15% [8]. Thus, in developed countries the overall occurrence of ADRs in geriatric hospitals may reach 20% and its nature follows the same pattern described above (mainly type A) [4]. Interestingly, the drug classes that often cause more type A ADRs are also those administered with greater frequency to geriatric patients in Brazil [9] and abroad [10].

Chronological age itself seems to have interference on the fate of drugs in the body; however, factors such as gender, ethnicity and the genotype of the patient generally have more importance [11]. Nevertheless, the organic changes that occur in the elderly could promote significant changes in pharmacokinetic and pharmacodynamic profiles.

*Corresponding author: Prof. Dr. Luis Eduardo M. Quintas, Laboratório de Farmacologia Bioquímica e Molecular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho 373, Bloco J, sala J-17, CCB, 21841-902, Rio de Janeiro, Brazil; Tel: +55-21-2562-6732; E-mail: lquintas@farmaco.ufrj.br

Received October 19, 2011; Accepted November 18, 2011; Published November 21, 2011

Citation: Quintas LEM, Gram KR5, da Silveira GPE, Lopes DVS, Póças ESC (2011) Pharmacokinetic Modifications and Drug-Drug Interactions in Clinical Monitoring of the Elderly: A Short Review. Pharmacol Anal Acta 2:141. doi:10.4172/2153-2435.1000141

Copyright: © 2011 Quintas LEM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
and therefore unexpected interactions. Thus, the possible effects of physiological changes caused by aging on the pharmacological processes and resulting interactions, comparing the risks and benefits of drug therapy in geriatric patients, are described.

Pharmacokinetic changes in geriatric patients

**Absorption:** Absorption involves the passage of drug molecules through the barrier(s) available between the administration site and the vascular compartment. Such process is crucial to the drugs that are administered via enteral or parenteral routes can reach their target and generate the desired pharmacological response.

For drugs administered orally, both the C$_{max}$ (maximum plasma concentration achieved by a drug), T$_{max}$ (time in which this is achieved) and AUC (area under the curve, giving the extent to which this process occurs) are directly influenced by the biochemical and physiological processes that govern the functioning of the gastrointestinal tract. The pH of the digestive tract, the rate of gastric emptying, intestinal smooth muscle tone, integrity of the intestinal surface (Kerckring folds, duodenal villi and microvilli), can significantly interfere with the absorption of drugs administered by this route. Any modification in these factors caused by different physiological, pathological or pharmacological conditions could cause failure of drug therapy.

As the elderly can present several slightly altered gastrointestinal properties (Table 1) and is more prone to chronic diseases, which often leads to the use of various types of medications concomitantly, special attention should be given to this group. Nevertheless, age usually does not affect the absorption of drugs that permeate the intestinal epithelium by passive diffusion in a clinically significant manner, with a few exceptions as indomethacin, prazosin, digoxin, and ciprofloxacin. Moreover, some ions (e.g., calcium, iron), vitamins, and maybe some nucleoside derivatives and gabapentin, which utilize the active transport processes and resulting interactions, comparing the risks and benefits of drug therapy in geriatric patients, are described.

Changes in pH of the gastrointestinal tract may also affect the dissolution of oral preparations. For example, the elevation of gastric pH may promote the early dissolution of formulations in the stomach or facilitated diffusion to cross this epithelium, can be absorbed at a slower rate [12]. In general, however, the enteral absorption is not a critical factor in the onset of interactions [13].

Changes in pH of the gastrointestinal tract may also affect the dissolution of oral preparations. For example, the elevation of gastric pH may promote the early dissolution of formulations in the stomach or facilitated diffusion to cross this epithelium, can be absorbed at a slower rate [12]. In general, however, the enteral absorption is not a critical factor in the onset of interactions [13].

| System            | Observed alteration                                      |
|-------------------|----------------------------------------------------------|
| General           | - body weight                                            |
|                   | - basal metabolic rate                                    |
|                   | - body water                                              |
|                   | - percentage of lean body mass                            |
|                   | - percentage of fat body mass                             |
| Circulatory       | - cardiac output                                          |
|                   | - tissue blood flow                                       |
|                   | - plasma albumin                                          |
| Gastrointestinal  | - gastric acid production                                 |
|                   | - gastric emptying rate                                   |
|                   | - intestinal motility                                     |
|                   | - blood flow                                              |
|                   | - absorptive surface                                      |
| Hepatic           | - mass                                                    |
|                   | - blood flow (arterial and/or portal)                     |
| Renal             | - glomerular filtration rate                              |
|                   | - tubular function                                        |
| Pulmonary         | - vital capacity                                          |

(↑) Increase; (↓) Decrease

**Table 1:** Physiological alterations in the elderly with potential to influence drug pharmacokinetics (modified from Klotz [6]).
this parameter is closely associated, and in direct proportion, to the $V_d$ [11,12]. Interestingly, the concomitant use of diuretics can reduce even more the extracellular fluid content, increasing the risk of toxicity [13]. Furthermore, the frail elderly with decreased weight has a decline in the percentage of body fat and increased $V_d$ even for lipid-soluble substances [13].

Plasma proteins, acceptors of most drugs used clinically, may display variations of concentration throughout aging. While serum albumin may be reduced by up to 20%, $\alpha_1$-acid glycoprotein may increase [11-14]. However, these changes have no clinical relevance in general, as evidenced by Grandison and Boudinot in their excellent review [19], except when other conditions trigger/exacerbate such variations such as malnutrition and disease (e.g., cancer) and when the drug has a high rate of binding to these proteins (Box 1) and/or has a low therapeutic index [11,13]. Certain anionic (acidic) drugs as valproate, naproxen, diazepam, ceftriaxone and enalapril (the active metabolite of the prodrug enalapril), which preferentially bind to albumin, and cationic (basic) drugs such as lidocaine, propranolol and chlorpromazine, which bind to the $\alpha_1$-acid glycoprotein, have their free fractions in plasma modified by age [19,20]. As the practice of polypharmacy is common to these patients, the presence of other drugs that may compete for binding to the same plasma protein in high-affinity sites may also be relevant. Well-known examples of this type of interaction in the case of albumin are warfarin, phenylbutazone, sulfonamides, phenytoin and valproate, and benzodiazepines, probenecid, semi-synthetic penicillins and intermediate-chain fatty acids [19,20].

**Biotransformation**

In the elderly, changes in the bioavailability of drugs promoted by changes in drug biotransformation, a step in the process of elimination pharmacokinetics, are relatively frequent. On average, the elderly presents 70% of the total capacity of biotransformation compared to young adults [11]. Chronic diseases, malnutrition, changes in liver physiology, and the use of multiple medications are the main factors that increase the potential of drug interactions in patients of this age group and undermine the therapeutic efficacy.

Physiologically, there is a reduction in liver blood flow and volume (about 30-40%) [12,21] although the quantitative changes of liver function and histology are minimal [22,23]. The discrepancy of the findings of reduced biotransformation, especially oxygen-dependent, in the elderly, led to proposal that aging is associated to pseudocapillarization of liver sinusoidal endothelium but without alteration of enzymatic content or activity [24-26]. These factors undermine the hepatic blood flow and, consequently, the efficient oxygenation of and arrival of nutrients to hepatocytes, the metabolism of these cells and, especially, the access of the drug to the liver to be biotransformed [25].

The nutritional condition of the patient also has an important influence on the rate of biotransformation. Malnutrition, characterized by protein deficiency, impairs the synthesis of enzymes directly, causing a significant impairment of metabolic and biotransforming capacity of tissues. Geriatric patients under the ideal weight have a lower extent of drug biotransformation than those of normal weight [27,28].

Besides the physiological changes and malnutrition, some chronic diseases that frequently affect patients in this age group may also cause relative hypoxia and other pathophysiological features typical of such disorders, i.e., enzymatic and hormonal alterations (hepatitis); lipid macrovesicles in hepatocytes, inflammation and Mallory corpuscles lesions (steatosis); vascular (due to diabetes mellitus) and systemic circulation disorder (cardiopathies).

Nonetheless, among the identified interactions including those discussed above, the drug-drug interactions are probably the most important in older people, especially those that alter the biotransformation process.

The biotransformation of xenobiotics occurs in enterocytes and/or hepatocytes in two phases: Phase I and/or phase II. Phase I (functionalization or non-synthetic phase) appears to be most influenced by age and is promoted by microsomal enzymes, among which stands out the mixed function oxidase system, known as cytochrome P450 (CYP), playing an oxidative function over lipophilic substrates [19]. CYP is a hemoprotein that presents several isozymes which differ in the inducibility and inhibitory pattern by certain substances, and probably also in the specificity of its catalytic action [19]. Among the CYP isoenzymes, the most commonly involved in drug biotransformation are CYP3A4, CYP2D6 (as a whole, these two are responsible for biotransformation of approximately 75% of all drugs), CYP1A2, CYP2C9, CYP2C19 and CYP2E1 [3]. Importantly, the activity and expression of the major isoform, CYP3A4, is dependent on normal liver function and is progressively decreased after its optimal performance in adulthood, reflecting the relative inability of biotransformation of older patients [3,11,21]. On the other hand, CYP2D6, which is responsible for ~25% of drug biotransformation, is particularly resistant to the relative hepatic impairment seen in the elderly [3,11,29]. Clinical problems of toxicity and ADRs can be minimized or avoided when knowing the CYP involved in the biotransformation of a given drug. In geriatric patients, several reports have shown that some drugs are poorly metabolized while others are not, although sometimes drugs from both metabolizing groups are targets of the same CYP (Table 2), indicating the complexity of the whole process [3]. In any case, it is important to bear in mind that elderly patients have a high incidence of CYP-metabolized drug treatment, which may increment the possibility of drug interactions and ADRs [30].

Although CYP activity and the resultant biotransformation ability depend on genetic polymorphism [29], this set of enzymes can undergo induction or inhibition, where the effect of a drug can influence the biotransformation of others. This leads to changes in the time of onset

| Low (0-25%) | Intermediate (25-75%) | High (>75%) |
|-------------|-----------------------|-------------|
| ampicillin | chloramphenicol | acetylsalicylic acid |
| antipyrine | digoxin | amphotericin B |
| cephalosporin | lincomycin | ethacrynic acid |
| cycloserine | nitrofurantoin | clobifrate |
| ethanol | penicillins | digoxin |
| kanamycin | pentobarbital | estrogens |
| lithium | quinine | glucocorticoids |
| paracetamol | secobarbital | griseofulvin |
| phenobarbital | tetracyclines | oral anticoagulants |
| streptomycin | thiopental | indomethacin |
| xanthines | trimethoprim | insulin |
| | | mefenamic acid |
| | | nalidixic acid |
| | | phenylbutazone |
| | | phenytoin |

**Box 1:** Binding capacity of drugs to plasma proteins.
and duration of effect, pharmacokinetic tolerance, therapeutic failure and/or worsening of toxicity.

The enzymatic inhibition is responsible for most drug interactions [31], and occurs by different mechanisms, but especially by the competition of two drugs for the same enzyme. The degree of inhibition depends on the permanence of the inhibitor drug in the body as well as its affinity to the biotransforming enzyme and dose administered [3]. Such inhibition of microsomal enzymes decreases the rate of hepatic and/or intestinal drug biotransformation as well as the total clearance, increases the serum concentrations of the free and total drug, the 1% of the drug in serum and clinical effects if the metabolites are inactive, and slows the production of metabolites. The main drugs involved in reversible enzyme inhibition are ketoconazole (non-competitive), erythromycin, nifedipine, omeprazole, progesterone, quinidine (competitive), fluconazole and fluoxetine (mixed) [19]. Other examples are shown in Table 4.

The process of enzyme induction, as it involves the synthesis of new enzymes via CYP gene transcription promoted by inducing drugs, usually takes longer and the degree of induction depends on the same variables described above for the enzyme inhibition [3].

Thus far, however, no conclusive comparative data on the presence or absence of differences between the extent of enzyme inhibition or induction in the elderly and young adults was obtained [13].

Many drugs are also biotransformed by phase II (conjugation or synthetic phase) involving reactions that produce conjugates such as acetylation, glucuronidation and sulfation, but these reactions are rarely affected by age [21,32]. Moreover, the amount of studies on the subject is much smaller than the reactions of phase I. Some examples can be seen in Table 3.

**Excretion**

Renal excretion of drugs is a phenomenon basically dependent on three processes: glomerular filtration, active tubular secretion and passive diffusion across the tubular epithelium. In glomerular filtration, molecules with molecular mass less than 20 kDa can reach up to the filtrate (glomerular ultrafiltrate) by passive diffusion through the fenestrae of glomerular capillaries. Thus, the free fraction of the vast majority of drugs are able to freely cross this barrier, but the fraction associated to plasma proteins such as albumin is impeded to undergo this process and may be subject to drug interactions – resulting both in an immediate increase in the plasma drug concentration and therefore an increase of its effects and toxicity, and in an augment of its availability for glomerular filtration. Drugs that did not go through glomerular filtration reach the peritubular capillaries of the proximal tubule and are submitted to the most effective mechanism of secretion of substances into the ultrafiltrate carrier systems consisting of independent and relatively non-selective transporters of organic acids and bases. Unlike glomerular filtration, this mechanism can make the maximum clearance of a substance even when bound to plasma proteins (e.g., penicillin). Thus, substances that may compete for binding to these transporters may result in drug interactions, such as reduced renal excretion of acetylsalicylic acid and methotrexate by competition with probenecid, which may be clinically relevant as in the case of penicillin. In the phenomenon of tubular reabsorption, passive

| Pharmacological class | Drug* | Impaired metabolism | CYP |
|-----------------------|-------|---------------------|-----|
| Antihypertensives     | nilidine, felodipine, diltiazem, propranolol, verapamil | yes | 3A4/3A5 2D6 2C9 several |
| Antiarrhythmics        | amiodarone, lidocaine | yes | 3A4/3A5 |
| Anxiolytics/hypnotics | triazolam, zolpidem, diazepam, midazolam | yes | 3A4/3A5 3A4 3A4/3A5 |
| Antidepressants        | amitriptyline, sertraline, fluoxetine, nortriptyline, venlafaxine, citalopram, imipramine | yes | 3A4/3A5 3A4/3A5 3A4/3A5 2D6 2C9 2C9 2C19 |
| Anticonvulsants        | carbamazepine, phenytoin | yes | 3A4/3A5 3A4/3A5 2C9 |
| Antipsychotics         | risperidone | no | 2D6 |
| Analgesics (opioids)   | fentanyl, afentanil | no | 3A4/3A5 3A4/3A5 3A4/3A5 |
| NSAIDs                 | paracetamol, naproxen, celecoxib, diclofenac, ibuprofen | yes | 3A4/3A5 2C9 2C9 several |
| Antibiotics            | cyclosporine | yes | 3A4/3A5 |
| Anticoagulants         | warfarin | yes | 2C9 |

*When the drug belongs to two or more pharmacological classes, it is presented in only one class

CYP – cytochrome P<sub>450</sub> NSAIDs – Non-steroidal anti-inflammatory drugs

Table 2: Phase I drug biotransformation characteristics in the elderly (modified from Tum Hein [12]).

| Drug A       | Interaction with drug B | Effect on A (mechanism) |
|--------------|-------------------------|-------------------------|
| Carbamazepine| enzymatic inhibitors, verapamil | ↑ (↑ biotransformation of A) |
| Cyclosporine | enzymatic inhibitors | ↑ (↑ biotransformation of A) |
|              | enzymatic inducers | ↑ (↑ biotransformation of A) |
| Digoxin      | amiodarone, diltiazem, verapamil, ACEI, NSAIDs | ↑ (↑ biotransformation of A) |
|              | atorvastatin, antilacs (with Mg²⁺ or Al³⁺), cholestyramine, colestipol | ↑ (unknown) |
| Lithium      | NSAIDs, diuretic fiazidicos | ↑ (↑ biotransformation of A) |
| Quinolones   | cholestyramine, colestipol | ↑ (↑ absorption of A) |
|              | enzymatic inhibitors, quinolones | ↑ (↑ biotransformation of A) |
| Theophylline | enzymatic inducers | ↑ (↑ biotransformation of A) |
| Thyroxine    | enzymatic inducers | ↑ (↑ biotransformation of A) |
| TCA          | enzymatic inhibitors* | ↑ (↑ biotransformation of A) |
|              | cholestyramine, colestipol | ↑ (↑ absorption and ↑ excretion of A) |
| Warfarin     | enzymatic inducers* | ↑ (↑ biotransformation of A) |
|              | cholestyramine, colestipol | ↑ (↑ absorption and ↑ excretion of A) |

*Examples of well-known inhibitors: amiodarone, fluconazole, miconazole, ketoconazole, erythromycin, clarithromycin, sulfonamides, omeprazole, cimetidine and ciprofloxacin.

Table 3: Pharmacological interactions of clinical importance in the elderly.
diffusion of non-ionized lipid-soluble substances from the proximal and distal tubular lumen into the bloodstream occurs, delaying their excretion. Therefore, the intratubular pH influences the excretion of organic acids and bases, since it changes their degree of ionization. This maneuver can be used in poisoning cases, where the increase in pH by sodium bicarbonate accelerates the excretion of drugs with acid characteristics such as barbiturates and acidification accelerates excretion of basic drugs such as amphetamines.

In the elderly, the most important pharmacokinetic alteration found is the deterioration of renal excretion, a consequence of reduced glomerular filtration rate, tubular secretion and renal blood flow (Table 1), resulting in an increased t½ for all drugs that are predominantly eliminated by the kidneys and, therefore, accumulation of dose or frequency of administration [21]. There is a gradual process of reduction of renal mass (15-30%) associated with glomerulosclerosis and cortical intracapillary hyalinosis as well as a parallel drop in the number of functional glomeruli and tubular secretion [12,13]. Humoral imbalances (e.g., endothelin, angiotensin II, prostaglandins PGE, and PGL) and significant renal histopathological changes such as the thickening of intrarenal vascular intimal layer and tubular basal membrane, infiltration of inflammatory cells and interstitial fibrosis may restrict the rate of infusion and glomerular filtration rate by 50% [11-14]. This becomes even more relevant because there is evidence that renal dysfunction may negatively affect the activity of biotransformation enzymes [11].

Dose adjustments should be made considering the patient’s renal capacity, measured as creatinine clearance. In young patients with stable renal function, serum creatinine levels are indicative of renal function. However, this estimate in the elderly is not appropriate since, in general, creatinine levels are reduced due to the decrease in muscle mass and lower protein degradation [9]. Thus, for predicting creatinine clearance there are some mathematical equations, of which the most widely accepted was described by Cockcroft and Gault (equation 1) [33]. However, these equations are not accurate for assessment in elderly patients and can generate under- or overestimation of creatinine clearance.

\[
\text{Creatinine clearance (mL/min)} = \\
(140 - \text{age}) \times \text{body weight (kg)} \times \frac{72 \times \text{serum creatinine (mg/mL)}}{0.85 \times \text{women}}
\]

* the result should be multiplied by 0.85 for women

On the other hand, elderly patients with elevated creatinine levels (> 1.5 mg/dL) should be analyzed with caution because these increased values suggest a significant decline in renal function compared to younger patients. Another alternative for calculating creatinine clearance equation is described in the study Modification of Diet in Renal Disease (MDRD) (equation 2) [36]. Despite its high complexity does not allow a routine calculation of creatinine clearance, it might give more accurate values than the Cockcroft and Gault formula, although it was not extensively tested in elderly patients [37].

\[
(2) \ GFR = 170 \times \left[ \frac{\text{Cr}_{\text{serum}}^{0.906} \times \left[ \frac{1}{\text{age}} \right]^{0.179} \times [0.762 \text{ for women}] \times [1.18 \text{ for africamerica}] \times \left[ \frac{\text{NU}_{\text{serum}}^{1.017} \times \left[ \text{Alb}_{\text{serum}}^{0.318} \right]}{\text{UN}_{\text{serum}} - \text{serum concentration of nitrogen urea, Alb}_{\text{serum}} - \text{albmin serum concentration}} \right]}{\text{Drugs}}
\]

As a consequence of the decline in glomerular filtration rate, there is an increased production of prostaglandins, a physiological change which seeks compensatory vasodilation of renal beds. Thus, non-steroidal anti-inflammatory drugs (NSAIDs) may prevent this compensatory mechanism, decreasing renal function. For that reason, the combination of NSAIDs with drugs that are primarily eliminated by the kidneys should be avoided, since they will have their concentrations increased. This kind of interaction is particularly sensitive in the case of drugs with narrow therapeutic index, such as digoxin [38]. In these cases, plasma concentrations should be monitored when NSAIDs are chronically prescribed [3,14].

Therefore, taking into account the decrease in renal elimination that generally occurs in elderly patients, we can conclude that interactions between drugs that are predominantly excreted by the kidneys and drugs that will somehow reduce both glomerular filtration and tubular secretion should be examined with greater caution in the elderly due to greater risk of increased plasma concentration and t½ of these drugs in comparison to young adults, achieving toxic drug levels and higher incidence of ADRs. Interestingly, however, a recent review brought attention to the fact that old age itself has a smaller influence on some pharmacokinetic parameters than what is generally believed, and thus may not be overestimated when considering the pharmacological therapy in aging population [37].

**Concluding Remarks**

Several pharmacological variables may be altered in the elderly, showing the full complexity of therapy in older age groups and the multiplicity of interactions and ADRs that can arise. Educational measures dealing with both students and professionals of health sciences in order to improve the knowledge of geriatric pharmacotherapy and the conduction of clinical studies in this population and preclinical experimental models are desirable goals and directly influence the performance of therapeutic interventions. Other proposals, such as the development of drug formulations suitable for the elderly, also integrate such a context. Over the past decades, social and scientific-technological advances are providing an ever-growing older society, where old age reaches progressively higher life span. Therefore, every effort is essential so that we can successfully tackle these challenges in the 21st century.

**References**

1. Aronson JK (2004) In defence of polypharmacy. Br J Clin Pharmacol 57: 119-120.
2. Fulton MM, Allen ER (2005) Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 17: 123-132.
3. Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 48: 133-143.
4. Routledge PA, O'Mahony MS, Woodhouse KW (2004) Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57: 121-126.

5. Corsonello A, Pedone C, Incalzi RA (2010) Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 17: 571-584.

6. Klotz U (1998) Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Ther 36: 581-585.

7. Le Couteur DG, Hillmer SN, Glasgow N, Naganathan V, Cumming RG (2004) Prescribing in older people. Aust Fam Physician 33: 777-781.

8. Brazilian Institute of Geography and Statistics (2000) Profile of the elderly responsible for households in Brazil. IBGE (Study & Research Series #9), Rio de Janeiro.

9. Rozenfeld S (2003) Prevalence, associated factors and medication misuse by the elderly: a review. Cad Saude Publica 19: 717-724.

10. Offerhaus L (1997) Drugs for the elderly. (2nd edn). WHO Regional Publications (European Series, vol 71), Copenhagen.

11. Shah RR (2004) Drug development and use in the elderly: search for the right dose and dosing regimen (parts I and II). Br J Clin Pharmacol 58: 452-469.

12. Turnheim K (2003) When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 38: 843-853.

13. Merle L, Laroche ML, Dantoine T, Charmes J-P (2005) Predicting and preventing adverse drug reactions in the very old. Drugs Aging 22: 375-392.

14. Hämmernlein A, Derendorf H, Lowenthal DT (1998) Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 35: 49-64.

15. O’Connor-Semmes RL, Kersey K, Williams DH, Lam R, Kock KM (2001) Effect of ranitidine on the pharmacokinetics of triazolam and α-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. Clin Pharmacol Ther 70: 126-131.

16. Hurwitz A, Ruhl CE, Kimler BF, Topp EM, Mayo MS (2003) Gastric function in the elderly: effects on absorption of ketoconazole. J Clin Pharmacol 43: 1002.

17. Evans RA, Antognini JF (2009) Perioperative drug therapy in elderly patients. Anesthesiology 110: 1176-1181.

18. Grandison MK, Boudinot FD (2000) Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet 38: 271-290.

19. Cusack BJ (2004) Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2: 274-302.

20. Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41: 67-76.

21. Klotz U (1998) Pharmacokinetics and drug metabolism in the elderly. J Gerontol Biol Sci Med Sci 53: 315-320.

22. Schmucker DL (1998) Aging and the liver: an update. J Gerontol Biol Sci Med Sci 53: 315-320.

23. Schmucker DL (2001) Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 18: 837-851.

24. Le Couteur DG, McLean AJ (1998) The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34: 359-373.

25. Le Couteur DG, Cogger VC, Markus AM, Harvey PJ, Yin ZL, et al. (2001) Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 33: 537-543.

26. McLean AJ, Cogger VC, Chong GC, Warren A, Markus AM, et al. (2003) Age-related pseudocapillarization of the human liver. J Pathol 200: 112-117.

27. Vestal RE (1997) Aging and pharmacology. Cancer 80: 1302-1310.

28. Walter-Sack I, Klotz U (1996) Influence of diet and nutritional status on drug metabolism, Clin. Pharmacokinet 31: 47-64.

29. Michalefs EL (1998) Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18: 84-112.

30. Cabrera MA, Dip RM, Furlan MO, Rodrigues SL (2009) Use of drugs that act on the cytochrome P450 system in the elderly. Clinics (São Paulo) 64: 273-278.

31. Johnson MD, Newkirk G, White JR Jr (1999) Clinically significant drug interactions: what you need to know before writing prescriptions. Postgrad Med 105: 193-195.

32. Durnas C, Loi CM, Cusack BJ (1990) Hepatic drug metabolism and aging. Clin Pharmacokinet 19: 359-389.

33. Cockcroft DW, Gault MH (1976) Prediction of creatinine-clearence from serum creatinine. Nephron 15: 314-327.

34. Fliser D, Bischoff I, Hansen A, Block S, Joest M, et al. (1999) Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 55: 205-211.

35. Oo C, Liu B, Hill G (2002) Change in creatinine clearance with advancing age. J Am Geriatr Soc 50: 1603-1604.

36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470.

37. Aymanns C, Keller F, Maus S, Hartmann B, Czock D (2010) Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 5: 314-327.

38. Siqueira-Batista R, Miranda-Filho N, Quintas LEM, Comêa AD (1992) Digitálicos. Rev Bras Med 70: 473-476.